Company intelligence / Profile preview

Revelle Aesthetics

Mountain View, California, United Statesrevelleaesthetics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Revelle’s lead product, Avéli®, is an FDA-cleared single-use disposable device for the long-term reduction of cellulite appearance in the buttocks and thigh areas of adult women. Clinical data support benefits through one year post-treatment. The procedure is minimally invasive, performed under local anesthesia, with targeted release of septa responsible for cellulite dimples.

Therapeutic areas: OtherDermatology
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Avéli

Commercial

Indications: Cellulite

Beyond the preview

Go deeper on Revelle Aesthetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revelle Aesthetics.

Explore the full profile